Lupin has received tentative approval for its Apixaban Tablets, 2.5 mg and 5 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Bristol-Myers Squibb Company's Eliquis Tablets, 2.5 mg and 5 mg.
Lupin's Apixaban Tablets, 2.5 mg and 5mg is the generic version of Bristol-Myers Squibb Company's Eliquis Tablets, 2.5 mg and 5 mg.
Eliquis Tablets, 2.5 mg and 5 mg had annual sales of approximately $6366 million in the US (IQVIA MAT September 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
